Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for the year. The pharmaceutical giant, known for its blockbuster COVID-19 products, is now forging ahead with a diversified growth strategy, reflecting a well-balanced portfolio of oncology, cardiology, and other in-demand […]
In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI (marstacimab-hncq) to prevent or reduce bleeding episodes in individuals aged 12 and above with hemophilia A or B without inhibitors. This marks a groundbreaking advancement in the treatment landscape for […]
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately 540 million ordinary shares in Haleon, one of the largest consumer healthcare companies in the world. This sale represents about 5.9% of Haleon’s total share capital and reflects Pfizer’s ongoing strategy to reduce its non-core assets. Pfizer, […]
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination with enfortumab vedotin for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) who have not received prior systemic therapy for this condition. This decision […]
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The study aimed to evaluate the effectiveness of the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in improving motor function among ambulatory boys with Duchenne muscular dystrophy (DMD) aged 4 to 7 […]
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration’s approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering gene therapy for adults with moderate to severe hemophilia B. This one-time treatment, designed to enable patients to internally produce the blood-clotting factor IX (FIX), offers a potential life-changing alternative […]
In a landmark decision, Pfizer Inc. (NYSE: PFE) has been granted marketing authorization by the European Commission (EC) for its 20-valent pneumococcal conjugate vaccine, PREVENAR 20, aimed at combating invasive pneumococcal disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children, and adolescents aged between 6 weeks and less than 18 years. […]
In a significant development for cervical cancer treatment, Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) have announced the European Medicines Agency’s (EMA) validation for review of the marketing authorization application (MAA) for tisotumab vedotin. This antibody-drug conjugate (ADC), developed to treat adult patients with recurrent or metastatic cervical cancer who have progressed on […]
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review of their recent application. This significant step involves a Type II variation application for PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab), targeting first-line treatment of adult patients with previously untreated […]
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab), a targeted immunotherapy designed for adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at […]